Ixazomib Citrate

證據等級: L5

預測適應症: 0 個

Ixazomib Citrate: Drug Repurposing Evaluation — Evidence Pack Incomplete

One-Sentence Summary

Ixazomib citrate is an oral proteasome inhibitor with established activity in multiple myeloma, but is currently not approved in Taiwan (0 TFDA licenses). The current Evidence Pack contains no TxGNN predicted indications, no mechanism of action data, and no safety records — a formal repurposing evaluation cannot proceed at this stage. All three core inputs required for evaluation are absent: target indication, supporting evidence, and safety baseline.

Quick Overview

Item	Content
Original Indication	Not recorded in Evidence Pack
Predicted New Indication	None — TxGNN prediction output absent
TxGNN Prediction Score	N/A
Evidence Level	L5 (no clinical or preclinical evidence in pack)
Taiwan Market Status	Not marketed (未上市)
Number of Authorizations (Taiwan)	0
Recommended Decision	Hold

Why No Evaluation Is Possible at This Stage

The Evidence Pack for ixazomib citrate was received with three structural gaps that collectively block evaluation:

1. No TxGNN prediction output. The predicted_indications array is empty. Without a candidate disease target generated by the TxGNN model, there is no repurposing hypothesis to assess. This is the foundational input for every downstream section of this report.

2. Mechanism of action data is unavailable (DG002 — High severity). The original_moa field is marked as a data gap. Without MOA, it is impossible to reason about mechanistic plausibility between a source indication and any potential new indication. The DrugBank query on 2026-03-26 returned a result (result_status: success, count 1), but the MOA field was not populated into the pack — this should be retrievable from DrugBank and resolved before the next run.

3. Safety baseline is absent (DG001 — Blocking severity). Both key_warnings and contraindications contain only [Data Gap]. The DDI query returned no results. Without a safety baseline, risk stratification of any repurposing candidate is not possible, and the pack cannot pass Stage 1 safety triage.

Taiwan Regulatory Status

Ixazomib citrate holds 0 TFDA marketing authorizations and is not currently marketed in Taiwan. No licensed dosage forms or approved indications are on record.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No Taiwan licenses on record

Safety Considerations

Please refer to the drug’s reference SmPC (e.g., NINLARO EU SmPC or FDA label) for safety information. Taiwan TFDA prescribing information has not yet been collected.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is missing its primary input (predicted_indications is empty), and two declared data gaps — missing MOA (DG002) and missing TFDA safety data (DG001, Blocking severity) — prevent safety triage from proceeding. No repurposing evaluation can be generated from this pack in its current state.

To proceed, the following is needed:

[Critical] Re-run TxGNN prediction pipeline for ixazomib citrate to populate predicted_indications — without this, the report has no target indication to evaluate
[Blocking] Collect TFDA prescribing information (仿單) to resolve DG001: download PDF from TFDA official site and extract warnings and contraindications
[High] Resolve DG002 by querying DrugBank API to populate original_moa and drugbank_id — the 2026-03-26 query returned a successful hit (result_count: 1) so this data appears to be accessible
[High] Populate original_indications in the drug object from DrugBank or TFDA records to enable mechanistic bridging analysis
After the above are resolved, re-generate the Evidence Pack and resubmit for evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.